Cardlytics, Inc. (NASDAQ:CDLX) Receives Average Recommendation of “Hold” from Brokerages

Cardlytics, Inc. (NASDAQ:CDLX) has received a consensus rating of “Hold” from the seven brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $6.92.

Several research analysts have recently weighed in on the stock. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research note on Thursday, November 7th. Finally, Evercore ISI started coverage on shares of Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective for the company.

Insider Buying and Selling

In other news, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at approximately $687,298.15. This represents a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Alexis Desieno sold 25,118 shares of Cardlytics stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the sale, the chief financial officer now directly owns 116,481 shares in the company, valued at $399,529.83. This trade represents a 17.74 % decrease in their position. The disclosure for this sale can be found here. 4.40% of the stock is owned by corporate insiders.

Institutional Trading of Cardlytics

Large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock worth $3,371,000 after acquiring an additional 73,484 shares in the last quarter. Marshall Wace LLP increased its holdings in Cardlytics by 6.8% during the 2nd quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock worth $6,685,000 after purchasing an additional 52,081 shares during the last quarter. RBF Capital LLC raised its position in shares of Cardlytics by 311.9% in the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Cardlytics by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock valued at $1,249,000 after buying an additional 11,388 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its stake in shares of Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after buying an additional 354,474 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Trading Up 2.1 %

Shares of CDLX opened at $3.81 on Friday. Cardlytics has a fifty-two week low of $2.89 and a fifty-two week high of $20.52. The company has a market capitalization of $193.63 million, a PE ratio of -0.62 and a beta of 1.53. The stock has a fifty day moving average of $3.93 and a two-hundred day moving average of $4.87. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. During the same period in the prior year, the firm posted ($0.26) earnings per share. The business’s quarterly revenue was down 15.1% compared to the same quarter last year. As a group, analysts forecast that Cardlytics will post -1.52 EPS for the current year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.